e7766

E7766 is a novel macrocycle-bridged stimulator of interferon genes (STING) agonist designed to activate the innate immune system and generate potent antitumor responses. It is a small molecule with a unique macrocyclic structure that enables pan-genotypic activity across all major human STING variants. Preclinical studies have demonstrated its ability to induce strong immune activation and durable antitumor effects in murine tumor models. The drug has been evaluated in Phase 1 clinical trials for advanced solid tumors and lymphomas but has not received regulatory approval as of now. Eisai developed E7766, with H3 Biomedicine (a subsidiary of Eisai) also involved in its clinical development[1][2][3][5][8].

Other names

macrocycle-bridged STING agonist E7766E7766 diammonium saltE-7766 diammonium saltE 7766 diammonium saltE7766 disodiumE-7766 disodiumE 7766 disodium